HIPPUTOPE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jun 1970
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HIPPUTOPE is an injectable diagnostic or therapeutic agent developed by Bracco, approved in 1970 as a New Drug Application (NDA). The specific mechanism of action and indication are not publicly detailed in available data, limiting characterization of its clinical role.
LOE Approaching
Product is in late-stage lifecycle with LOE approaching; commercial teams should expect portfolio transition planning and potential downsizing within the next 2–5 years.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
HIPPUTOPE currently shows zero linked job openings, reflecting its late-lifecycle status and low commercial activity. Career opportunity on this product is minimal; professionals should prioritize roles in growth-stage or newly launched franchises within the Bracco portfolio.
Brand ManagerField Sales Representative
Worked on HIPPUTOPE at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.